Eosinophilic Activation in Cystic Fibrosis

Overview

Journal Thorax

Date 1994 May 1

PMID 8016773

Citations 21

Authors

D Y Koller

M Gotz

I Eichler

R Urbanek

Affiliations

Soon will be listed here.

Abstract

Background: The neutrophil is a potent contributor to pulmonary destruction in cystic fibrosis. Since eosinophils also possess destructive potential the involvement of eosinophils in cystic fibrosis has been investigated.

Methods: Eosinophil numbers and levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, were determined in the serum of 42 patients with cystic fibrosis and in the sputum of 10 of them. To determine neutrophil activation levels of myeloperoxidase (MPO) were also measured.

Results: In cystic fibrosis increased serum levels of ECP were detected compared with healthy non-atopic subjects. Serum ECP levels were not related to the peripheral blood eosinophil count. A strong correlation with ECP concentrations in sputum indicated that the level of ECP in serum was representative of its pulmonary level. Levels of MPO were also increased in cystic fibrosis. A strong correlation was found between MPO and pulmonary function. In addition, ECP was related to arterial oxygen and carbon dioxide tensions. Antibiotic treatment reduced neutrophil activation without effect on ECP levels.

Conclusions: Until now Pseudomonas aeruginosa and neutrophils were held to be primarily responsible for progressive tissue damage in cystic fibrosis. The results of this study suggest that eosinophils might also participate in such pulmonary destruction.

Citing Articles

Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.

Chatterjee P, Moss C, Omar S, Dhillon E, Hernandez Borges C, Tang A J Fungi (Basel). 2024; 10(9).

PMID: 39330416 PMC: 11433030. DOI: 10.3390/jof10090656.

in chronic lung disease: untangling the dysregulated host immune response.

Nickerson R, Thornton C, Johnston B, Lee A, Cheng Z Front Immunol. 2024; 15:1405376.

PMID: 39015565 PMC: 11250099. DOI: 10.3389/fimmu.2024.1405376.

The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis.

Mehta A, Lee I, Li G, Jones M, Hanson L, Lonabaugh K Allergy Asthma Clin Immunol. 2023; 19(1):66.

PMID: 37525180 PMC: 10391773. DOI: 10.1186/s13223-023-00822-2.

The Impact of CFTR Modulator Triple Therapy on Type 2 Inflammatory Response in Patients with Cystic Fibrosis.

Mehta A, Lee I, Li G, Jones M, Hanson L, Lonabaugh K Res Sq. 2023; .

PMID: 37215020 PMC: 10197784. DOI: 10.21203/rs.3.rs-2846739/v1.

Association between Cystic Fibrosis exacerbations, lung function, T2 inflammation and microbiological colonization.

Albon D, Zhang L, Patrie J, Jones M, Li Z, Noonan E Allergy Asthma Clin Immunol. 2023; 19(1):15.

PMID: 36849900 PMC: 9969710. DOI: 10.1186/s13223-023-00760-z.

References

Bedrossian C, Greenberg S, Singer D, Hansen J, Rosenberg H . The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol. 1976; 7(2):195-204. DOI: 10.1016/s0046-8177(76)80023-8. View

SHWACHMAN H, KULCZYCKI L . Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958; 96(1):6-15. DOI: 10.1001/archpedi.1958.02060060008002. View

Venge P, Zetterstrom O, Dahl R, Roxin L, Olsson I . Low levels of eosinophil cationic proteins in patients with asthma. Lancet. 1977; 2(8034):373-5. DOI: 10.1016/s0140-6736(77)90303-8. View

Olsson I, Olofsson T, Ohlsson K, Gustavsson A . Serum and plasma myeloperoxidase, elastase and lactoferrin content in acute myeloid leukaemia. Scand J Haematol. 1979; 22(5):397-406. DOI: 10.1111/j.1600-0609.1979.tb00437.x. View

Frigas E, Loegering D, Gleich G . Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest. 1980; 42(1):35-43. View

Goldstein W, DORING G . Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis. 1986; 134(1):49-56. DOI: 10.1164/arrd.1986.134.1.49. View

Gleich G, Adolphson C . The eosinophilic leukocyte: structure and function. Adv Immunol. 1986; 39:177-253. DOI: 10.1016/s0065-2776(08)60351-x. View

Hastie A, Loegering D, Gleich G, Kueppers F . The effect of purified human eosinophil major basic protein on mammalian ciliary activity. Am Rev Respir Dis. 1987; 135(4):848-53. DOI: 10.1164/arrd.1987.135.4.848. View

Perruchoud A, Brundler H, Godly R, IMHOF E, Herzog H . Broxaterol (Z.1170), a new oral beta 2-agonist compared with salbutamol. Respiration. 1987; 51(2):113-8. DOI: 10.1159/000195177. View

10.

Mohammed J, Mohammed B, Pawluk L, Bucci D, Baker N, DAVIS W . Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum. J Lab Clin Med. 1988; 112(6):711-20. View

11.

Flavahan N, Slifman N, Gleich G, Vanhoutte P . Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis. 1988; 138(3):685-8. DOI: 10.1164/ajrccm/138.3.685. View

12.

Eichler I, Joris L, Hsu Y, Van Wye J, Bram R, Moss R . Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. J Clin Invest. 1989; 84(6):1794-804. PMC: 304057. DOI: 10.1172/JCI114364. View

13.

Suter S, Schaad U, Roux-Lombard P, Girardin E, Grau G, Dayer J . Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis. 1989; 140(6):1640-4. DOI: 10.1164/ajrccm/140.6.1640. View

14.

Bousquet J, Chanez P, Lacoste J, Barneon G, Ghavanian N, ENANDER I . Eosinophilic inflammation in asthma. N Engl J Med. 1990; 323(15):1033-9. DOI: 10.1056/NEJM199010113231505. View

15.

McElvaney N, Hubbard R, Birrer P, Chernick M, CAPLAN D, Frank M . Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991; 337(8738):392-4. DOI: 10.1016/0140-6736(91)91167-s. View

16.

Lundgren J, Davey Jr R, Lundgren B, Mullol J, Marom Z, Logun C . Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion. J Allergy Clin Immunol. 1991; 87(3):689-98. DOI: 10.1016/0091-6749(91)90390-a. View

17.

Berger M . Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?. Clin Rev Allergy. 1991; 9(1-2):119-42. DOI: 10.1007/978-1-4612-0475-6_8. View

18.

Garofalo R, Kimpen J, Welliver R, Ogra P . Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr. 1992; 120(1):28-32. DOI: 10.1016/s0022-3476(05)80592-x. View

19.

Azzawi M, Johnston P, Majumdar S, Kay A, Jeffery P . T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis. 1992; 145(6):1477-82. DOI: 10.1164/ajrccm/145.6.1477. View

20.

Olsson I, Venge P, Spitznagel J, Lehrer R . Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest. 1977; 36(5):493-500. View